secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001437749-24-024725
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma divests Consumer Health business to private e-commerce firm; receives royalty payments
--------------------------------------------------------------------------------

- Divested Consumer Health (Innovus Pharmaceuticals) to an undisclosed private e-commerce company after winding down operations.
- Aytu receives revenue-based royalty payments on future sales of former Consumer Health products.
- Company now focuses solely on its prescription pharmaceutical segment to drive profitability.
- Wind down eliminated materially all remaining Consumer Health expenses; near adjusted EBITDA breakeven during wind-down.
- Closure of Grand Prairie, TX manufacturing site expected to further enhance operating margins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924024725/0001437749-24-024725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924024725/aytu20240730_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-024725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer